183 related articles for article (PubMed ID: 29704172)
1. A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2018 Jul; 46(1):95-101. PubMed ID: 29704172
[TBL] [Abstract][Full Text] [Related]
2. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
3. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice.
Zhu B; Kuhel DG; Witte DP; Hui DY
Am J Pathol; 2000 Dec; 157(6):1839-48. PubMed ID: 11106557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
6. CCL5 deficiency reduces neointima formation following arterial injury and thrombosis in apolipoprotein E-deficient mice.
Czepluch FS; Meier J; Binder C; Hasenfuss G; Schäfer K
Thromb Res; 2016 Aug; 144():136-43. PubMed ID: 27337700
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice.
Noels H; Zhou B; Tilstam PV; Theelen W; Li X; Pawig L; Schmitz C; Akhtar S; Simsekyilmaz S; Shagdarsuren E; Schober A; Adams RH; Bernhagen J; Liehn EA; Döring Y; Weber C
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1209-20. PubMed ID: 24723559
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.
Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Eur J Pharmacol; 2018 Feb; 820():222-228. PubMed ID: 29269019
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Morishima Y; Shibutani T; Noguchi K; Ito Y; Honda Y
J Thromb Thrombolysis; 2021 Jul; 52(1):9-17. PubMed ID: 33534029
[TBL] [Abstract][Full Text] [Related]
11. Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice.
Ohno K; Tomizawa A; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Res; 2015 Dec; 136(6):1245-51. PubMed ID: 26489728
[TBL] [Abstract][Full Text] [Related]
12. Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling.
Klutho PJ; Pennington SM; Scott JA; Wilson KM; Gu SX; Doddapattar P; Xie L; Venema AN; Zhu LJ; Chauhan AK; Lentz SR; Grumbach IM
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2594-604. PubMed ID: 26449752
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice.
Zhu Y; Farrehi PM; Fay WP
Circulation; 2001 Jun; 103(25):3105-10. PubMed ID: 11425776
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase.
Moore ZW; Hui DY
J Lipid Res; 2005 Oct; 46(10):2083-90. PubMed ID: 16061951
[TBL] [Abstract][Full Text] [Related]
16. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice.
Schober A; Knarren S; Lietz M; Lin EA; Weber C
Circulation; 2003 Nov; 108(20):2491-7. PubMed ID: 14581398
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
18. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
Schober A; Zernecke A; Liehn EA; von Hundelshausen P; Knarren S; Kuziel WA; Weber C
Circ Res; 2004 Nov; 95(11):1125-33. PubMed ID: 15528472
[TBL] [Abstract][Full Text] [Related]
19. Role of macrophage colony-stimulating factor in the development of neointimal thickening following arterial injury.
Mishra V; Sinha SK; Rajavashisth TB
Cardiovasc Pathol; 2016; 25(4):284-292. PubMed ID: 27135205
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Morishima Y; Honda Y; Kamisato C
Pharmacology; 2019; 103(1-2):17-22. PubMed ID: 30343300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
